A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-003698-13

A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE)

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this trial is to evaluate the efficacy of atacicept compared to placebo in preventing new flares in subjects with SLE.


Critère d'inclusion

  • Systemic Lupus Erythematosus